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Abstract Recurrent aphthous stomatitis (RAS; recurrent
aphthous ulcers; canker sores) belongs to the group of
chronic, inflammatory, ulcerative diseases of the oral
mucosa. Up to now, the etiopathogenesis of this condition
remains unclear; it is, however, considered to be multi-
factorial. The results of currently performed studies
indicate that genetically mediated disturbances of the
innate and acquired immunity play an important role in the
disease development. Factors that modify the immunologic
response in RAS include: food allergies, vitamin and
microelement deficiencies, hormonal and gastrointestinal
disorders (e.g., celiac disease, Crohn’s disease, ulcerative
colitis), some viral and bacterial infections, mechanical
injuries and stress. In this paper, we presented the main
etiopathogenetic factors of RAS with a special emphasis on
the mechanisms of the immune response modification.
Moreover, we discussed the crucial clinical symptoms and
types of RAS together with epidemiologic data based on
the current medical literature reports and our own
observations.
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Introduction
Recurrent aphthous stomatitis (RAS; recurrent aphthous
ulcers; canker sores) belongs to the group of chronic,
inflammatory diseases of the oral mucosa (Field and Allan
2003; McCullough et al. 2007; Rogers 1997; Scully and
Porter 2008). The most characteristic symptom of the
disease is the recurrent onset of single or multiple painful
erosions and ulcers that appear mainly on unattached oral
mucosa of the lips, cheeks and tongue. Occasionally the
lesions may also be observed on strongly keratinized pal-
atal and gingival mucosa. The eruptions are surrounded by
a characteristic erythematous halo and covered with fibrous
coating (Chavan et al. 2012; Rogers 1997). Considering the
clinical features, three main types of recurrent aphthae can
be distinguished: minor aphthae (Mikulicz’s aphthae;
MiRAS), major aphthae (Sutton’s aphthae; MaRAS) and
herpetiform aphthae (HeRAS) (Burruano and Tortorici
2000; Chattopadhyay and Chatterjee 2007; Natah et al.
2004; Tappuni et al. 2013; Woo and Sonis 1996). The
comparison of the most crucial clinical features of RAS
according to their classification is presented in Table 1.
Recurrent aphthae appearing simultaneously on the oral
and genital mucosa are one of the symptoms of Behc¸et’s
syndrome, a systemic, inflammatory disease with a sus-
pected autoimmune background (Freysdottir et al. 1999;
Lehner 1978; Williams and Lehner 1977).
The prevalence of RAS in the general population ranges
between 5 and 25 %. Such significant differences have
been reported depending on the origin of the examined
groups and populations as well as on the studies’ design
and methodology (Liang and Neoh 2012; Rogers 1997;
Scully et al. 2003; Shashy and Ridley 2000). The presence
of aphthae directly during the clinical examination is
detected in a lower percentage of the examined subjects
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when compared with the studies based on the information
from the patient’s history. However, the recurrent nature of
this condition makes the data from the medical history very
relevant in defining the final prevalence of the disease. The
comparison of RAS prevalence evaluated based on the
results of clinical examination and the information from
patient’s history in some international research in correla-
tion with age is presented in Table 2.
The second life decade is considered as a peak period of
the RAS occurrence with the first episode in childhood or
in later life stages. As in the other diseases with possible
autoimmune-mediated diseases, early age at onset does not
necessarily need to be related with a worse prognosis
(Amador-Pattaroyo et al. 2012). Based on epidemiologic
observations, MaRAS appears more frequently in younger
patients, while HeRAS affects most commonly people in
third life decade (Chattopadhyay and Chatterjee 2007;
Natah et al. 2004; Tappuni et al. 2013; Woo and Sonis
1996). The mechanism of the development of particular
type of RAS in correlation with patient’s age has not been
clearly understood so far. Although the RAS is generally a
common oral mucosal condition; herpetiform type is
observed rarely, which makes the comparisons between the
types’ occurrence difficult, as most of the reports refer to
MaRAS or MiRAS. More profound analysis in this matter
is definitely indicated. Generally, the severity and fre-
quency of the episodes vary individually; however, it
usually decreases with age, as presented in Table 2
(McCullough et al. 2007; Reichart 2000; Shulman 2004;
Sook-Bin and Sonis 1996; Wolach et al. 2012). The
reduced occurrence of RAS in elderly in comparison to
young patients may partially result from age-dependent
alterations in the innate and the adaptive components of the
immune system, described as immunosenescence and
‘‘inflamm-aging’’ (DeVeale et al. 2004; Franceschi et al.
2000; Plowden et al. 2004; Senovilla et al. 2013). In
elderly, the neutrophils’ chemotactic and phagocytic
capacity decreases and the reduced proportion of naive T














other RAS types (%)
Localization
MiRAS 5–10 \10 Shallow No 10–14 2 life
decade
75–90 Non-keratinized oral mucosa. Often: lips,
buccal regions, tongue margins
MaRAS [10 1–3 Deep Yes [14 1 and 2 life
decade
10–15 Keratinized and non-keratinized oral
mucosa. Often: soft palate
HeRAS \5 [10 Shallow No 10–14 3 life
decade
5–10 Non-keratinized oral mucosa. Often: floor
of the mouth, ventral surface of the
tongue
Table 2 RAS prevalence in the clinical examination and based on the patient’s history in the literature reports
RAS prevalence (%) Population studies References
Clinical examination Patient’s history Country Number of participants Age of participants
1.2 USA 7,785 17–39 Rivera-Hidalgo et al. (2004)
0.59 9,450 C40
1.03 USA 33,994 \1 to C60 Chattopadhyay and Chatterjee (2007)
1.2 Turkey 765 5–95 Mumcu et al. (2005)
1.4 18.3 Germany 655 35–44 Reichart (2000)
1.0 6.9 1,367 65–74
9.7 Slovenia 555 15–65 Kovacˇ-Kovacˇicˇ and Skalericˇ (2000)
78.1 Jordan 684 13–68 Safadi (2009)
2 27.3 Poland 814 14–18 Go´rska (1997a)
7.6 Poland 1,216 10–79 Szponar et al. (2006)
10.0 Poland 1,281 NDa Konopka and Mendak (2004)
3.6 Poland 1,500 NDa Bizon´-Wro´blewska et al. (1997)
a Not defined in the study project
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cells relative to their memory counterparts occurs (Mah-
easwari et al. 2013; Stankiewicz and Stasiak-Barmuta
2011). Apart from the shifts in population types, immune
cells also exhibit altered cytokine production and respon-
siveness, reduced proliferative responses, signal
transduction defects and diminished antigen recognition
(Campisi et al. 2009; Maheaswari et al. 2013; Wardzyn´ska
and Kowalski 2009). The prevalence of autoimmune dis-
eases is relatively low in elderly patients also due to age-
related increase in peripheral CD4?CD25highFOXP3?
T-regulatory cells (Vadasz et al. 2013). This process may
also be involved in RAS.
Apart from the age-related differences in the prevalence,
the condition is found three times more often in white citi-
zens than in Afro-Americans (Matranga et al. 2012). Also
non-smoking subjects are more prone to develop RAS in
comparison to tobacco smokers and smokeless tobacco users
(Chattopadhyay and Chatterjee 2007; Grady et al. 1992;
Rivera-Hidalgo et al. 2004). Many epidemiologic studies
confirmed the higher incidence of RAS in people with a high
socio-economic status (McCullough et al. 2007; Rivera-
Hidalgo et al. 2004). Also females seem to be in a higher risk
of the disease development in comparison to males
(McCullough et al. 2007; Rivera-Hidalgo et al. 2004).
Minor (Mikulicz) aphtha on the lower lip in a male
patient of the Department of Oral Mucosa Diseases is
presented in Fig. 1.
Etiopathogenesis of RAS
The etiopathogenesis of RAS so far remains not fully
understood. The potential trigger factors include: genetic
predisposition, viral and bacterial infections, food allergies,
vitamin and microelement deficiencies, systemic diseases
(e.g., celiac disease, Crohn’s disease, ulcerative colitis,
AIDS), increased oxidative stress, hormonal defects,
mechanical injuries and anxiety (Bilgili et al. 2013; Field and
Allan 2003; Koybasi et al. 2006; McCullough et al. 2007;
Natah et al. 2004; Scully and Porter 2008). Recently, also the
atopic background of the condition has been suggested
(Veller-Fomasa and Gallina 2006). In genetically predis-
posed patients, the effect of certain trigger factors initiates
the cascade of proinflammatory cytokines, directed against
selected regions of the oral mucosa. The microscopic
observation of the aphtha region reveals a massive leuko-
cytic infiltration, which varies depending on the disease
duration and severity. In the initial phase which precedes the
ulcer formation, monocytes and lymphocytes (mainly of the
T type) together with single mast and plasmatic cells accu-
mulate under the basal cell layer. In more advanced stages,
polynuclear leukocytes dominate in the center of the ulcer,
while on the lesion border the abundant mononuclear cell
infiltration can be observed (Mills et al. 1980; Poulter and
Lehner 1989). According to Poulter and Lehner (1989), this
characteristic of the inflammatory infiltration is not
Fig. 1 Minor (Mikulicz) aphtha on the lower lip in a patient of the
Department of Oral Mucosa Diseases Fig. 2 Modifying factors of the immunologic response in RAS
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exclusively specific to RAS and does not differ from the one
observed in Behc¸et’s syndrome, erythema multiforme, lupus
erythematosus and traumatic ulcers.
Factors that modify the course of the immune response
in RAS are presented in Fig. 2.
Genetic Predisposition
First reports on the role of genetic predisposition in the
development of RAS are dated to the middle 1960s of the
twentieth century. Based on the observation of the families
suffering from RAS, Ship (1965) and Miller et al. (1977)
propounded the autosomal recessive or multigene mode of
inheritance with modifying influence of the environment.
The role of genetic factors in the etiopathogenesis of
recurrent aphthae was confirmed in further studies of rela-
tives and twins with RAS, where the positive family history
of the disease was reported in 24–46 % of cases (Rogers
1997; Scully and Porter 2008). The disease in parents sig-
nificantly influences the risk of RAS and the course of the
condition in their children—patients with a positive family
history of RAS suffer more frequent recurrences and more
severe course of the disease comparing to those with a
negative RAS family history (Almoznino et al. 2013;
Lehner 1978; Yilmaz and Cimen 2010). Moreover, in both,
RAS and Behc¸et’s syndrome, the risk of the disease
development was higher in monozygotic twins than in
dizygotic ones (Kobayashi et al. 2005; Yilmaz and Cimen
2010). The genetic risk factors that modify the individual
susceptibility to RAS include various DNA polymorphisms
distributed in the human genome, especially those related
with the alterations in the metabolism of interleukins (IL-
1b, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12), interferon (IFN)-c
and tumor necrosis factor (TNF)-a (Akman et al. 2006,
2008; Bazrafshani et al. 2002, 2003; Bun˜o et al. 1998;
Guimara˜es et al. 2006, 2007; Hall et al. 2000; Kalkan et al.
2013; Pekiner et al. 2012). The role of DNA polymorphisms
in serotonin transporter gene, endothelial nitric oxide syn-
thase gene and cell adhesion molecule genes has also been
considered (Alkhateeb et al. 2013; Gallo et al. 2012; Ka-
rasneh et al. 2005, 2009; Kim et al. 2003; Oksel et al. 2006;
Salvarani et al. 2002; Victoria et al. 2005; Wang and Wang
2000). Other researchers reported the correlation between
the selected HLA allele and the increased risk of RAS and
Behc¸et’s syndrome (Albanidou-Farmaki et al. 2008; Chal-
lacombe et al. 1977; Sun et al. 2001). In patients with RAS,
a higher incidence of HLA-A33, HLA-B35 and HLA-B81
(Wilhelmsen et al. 2009), HLA-B12 (Lehner et al. 1982),
HLA-B51 (O¨zdemir et al. 2009), HLA-DR7 and HLA-DR5
and lower incidence of HLA-B5 and HLA-DR4 (Albani-
dou-Farmaki et al. 1988; Gallina et al. 1985) was observed
when compared to healthy controls.
Bacterial and Viral Infections
Among the potential factors with the ability to modify the
immunologic response and to invoke recurrent aphthae in
predisposed subjects some authors mention bacterial
(Streptococcus oralis, Helicobacter pylori) and viral (her-
pes simplex virus, varicella-zoster virus, cytomegalovirus,
adenoviruses) antigens. The studies’ results, however, are
ambiguous and conflicting (Barile et al. 1963; Donatsky
1976; Natah et al. 2004; Shimoyama et al. 2000; Sook-Bin
and Sonis 1996). The elevated serum level of antibodies
against some streptococcal strains in RAS patients reported
in the 1960s was not confirmed in latter studies, similarly
in the case of antibodies against H. pylori (Barile et al.
1963; Donatsky 1976; Fritscher et al. 2004; Mansour-
Ghanaei et al. 2005; Shimoyama et al. 2000). Tas et al.
(2013) proved the beneficial effect of H. pylori eradication
in patients with RAS. The underlying mechanism, how-
ever, is rather related with the increase in serum vitamin
B12 levels after the eradication than with the direct action
of the bacteria. The attempts to isolate herpes simplex,
cytomegalovirus, varicella-zoster and Epstein-Barr viral
DNA from the biologic material collected from aphthae
and mononuclear peripheral blood cells were successful
only in single case of RAS, which also does not confirm the
direct role of viruses in the etiopathogenesis of the condi-
tion (Natah et al. 2004). Also Greenspan et al. (1985)
concluded that neither cell-mediated hypersensitivity to
streptococcal or viral antigens nor cross-reactivity between
oral mucosal and streptococcal antigens is likely to play a
role in the pathogenesis of RAS.
Food Allergies and Microelement Deficiencies
In some patients with RAS, the deficiency in hematins
(iron, folic acid, vitamin B12) was revealed (Khan et al.
2013; Lopez-Jornet et al. 2013; Natah et al. 2004; Olson
et al. 1982; Scully and Porter 2008; Sook-Bin and Sonis
1996; Volkov et al. 2009); however, their modifying
influence on the course of the immune response in RAS
seems to be limited. In research by Lalla et al. (2012),
Nolan et al. (1991a, b), Porter et al. (1992) and Haisraeli-
Shalish et al. (1996), the supplementation of lacking
microelements modified the disease course only in a
small percentage of patients. Contrary, Volkov et al.
(2009) observed positive effects of the oral vitamin B12
supplementation in RAS subjects regardless of the initial
serum levels of this microelement. Some reports on the
role of zinc deficiency in RAS were also published. Up
to now, the theory was not unequivocally confirmed and
the studies’ results are conflicting (Endre 1991; Pang
1992).
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According to some researchers, also the exposition to
some food ingredients, e.g., chocolate, gluten, cow milk,
preservatives, nuts and food coloring agents may induce
the pro-inflammatory cascade in RAS (Natah et al. 2004;
Eversole et al. 1982; Sook-Bin and Sonis 1996; Wardhana
2010). In some patients, the clinical improvement was
observed after inducing the elimination diet. In their dou-
ble-blind study, Hunter et al. (1993) concluded that also the
placebo-effect probably modifies the course of RAS—the
clinical improvement was observed in both study groups:
patients on real elimination diet and patients on a regular
diet, exposed to potential trigger food ingredients. Mean-
while, Tarakji et al. (2012) did not confirm any important
role of dietary habits in development of RAS.
Systemic Diseases and Hormonal Imbalance
Based on many studies’ results, recurrent aphthae appear
more frequently in patients with gastro-intestinal distur-
bances, mainly those from the group of chronic
inflammatory bowel diseases (Crohn’s disease, ulcerative
colitis) and celiac disease (Aydemir et al. 2004; Hunter
et al. 1993; Olszewska et al. 2006; Rogers 1997; Scully and
Porter 2008). This correlation may partially result from the
food and microelement deficiencies—a characteristic
complication in this group of the diseases (Natah et al.
2004). The coincidence of aphthae with inflammatory
bowel diseases and celiac disease may also be related with
autoimmune reactions, assumed as a background of all the
mentioned conditions (Woz´niak-Stolarska et al. 2003).
Aphthae were also a frequent finding in HIV-infected
persons, who manifested the disproportion of CD4 and
CD8 lymphocytes together with decreased neutrophil count
(MacPhail et al. 1991; Miziara et al. 2005; Muzyka and
Glick 1994; Nesti et al. 2012).
Some reports mention also the correlation between the
serum levels of sexual hormones and the course of RAS.
Exacerbations of the condition were observed mainly in the
luteal phase of the menstrual cycle and during the meno-
pause, while the remissions seem to appear often during
pregnancy and in women on contraceptives (Natah et al.
2004; Scully et al. 2003; Sook-Bin and Sonis 1996).
Mechanical Injuries
In many RAS-predisposed patients, the lesions appear on
the oral mucosa shortly after mechanical irritation of the
area; however, the mechanism of this reaction remains not
fully understood (Natah et al. 2004, Scully et al. 2003,
Sook-Bin and Sonis 1996, Wray et al. 1981). Polan´ska
et al. (2006) suggested the role of neutrophil elastase in the
process of post-traumatic formation of aphthous ulcer. On
the other hand, based on the epidemiologic observations,
most of the researchers indicate the lower incidence of
RAS in smokers in comparison to non-smoking subjects,
with a correlation with habit duration and severity (Axell
and Henricsson 1985; Bittoun 1991; Sawair 2010; Tuzun
et al. 2000). That could be explained by a higher level of
oral mucosa keratinization in response to smoking, which
makes it less prone to injury and irritation (Natah et al.
2004; Scully et al. 2003; Sook-Bin and Sonis 1996). Nic-
otine and its metabolites can also decrease the level of pro-
inflammatory cytokines (TNF-a, IL-1 and IL-6) and
increase the level of anti-inflammatory IL-10 (Subraman-
yam 2011). Also smokeless tobacco products seem to
decrease the risk of RAS development (Grady et al. 1992).
Stress
Another described factor potentially related with RAS
exacerbations is stress (Natah et al. 2004; Keenan and
Spivakovksy 2013; Scully et al. 2003; Sook-Bin and Sonis
1996; Volkov et al. 2009; Zadik et al. 2012). According to
some authors, it rather triggers the onset of the episode than
influences its duration (Huling et al. 2012; Keenan and
Spivakovksy 2013). Psychogenic effects modify the
immune response also in the other conditions with a sus-
pected autoimmune background, like lichen planus and
chronic inflammatory bowel diseases (Soto Araya et al.
2004).
Mechanisms of the Immune Response in RAS
The basic mechanisms of the immunologic response dis-
ruption in RAS are illustrated in Fig. 3.
One of the important factors that may induce and deter-
mine the type of the immune response in the human body is
the cytokines (Konopka et al. 1995). Th1 type cytokines,
which include: IL-2, IL-12, IFN-c and TNF-a, determine the
predisposition towards autoimmunisation, induce the cellu-
lar type response and stimulate the secretion of IgG. Th2 type
cytokines, including: IL-4, IL-5, IL-10 and IL-13, manifest
anti-inflammatory properties, stimulate the humoral immune
response and the secretion of IgE. Strong anti-inflammatory
effect is contributed also to another cytokine called trans-
forming growth factor (TGF)-b, secreted mainly by the
T-regulator lymphocytes (Bun˜o et al. 1998; Lewkowicz et al.
2004). It was found that aphthous ulcer develops in response
to the enhanced immunologic reaction against particular
regions of the oral mucosa (Borra et al. 2004; Eversole 1994;
Lewkowicz et al. 2004). This reaction occurs in a result of
improperly initiated cascade of cytokines, which activate
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certain immune processes (Borra et al. 2004; Lewkowicz
et al. 2004). It was found that in patients with RAS, the
immune system’s function become disrupted in response to
some kind of not yet defined trigger factor, which may
include viral and bacterial antigens or stress. In many reports
also the role of the autoimmunisation in the disease devel-
opment was emphasized (Borra et al. 2004; Go´rska 1997b;
Hietanen et al. 2012; Malmstro¨m et al. 1983). Both types of
the immune response: natural and acquired (humoral and
cellular) may become disturbed in patients with RAS, which,
among the others, manifests with neutrophils’ reactivation
and hyper-reactivity, elevated concentration of the comple-
ment ingredients, increased number of NK cells and B
lymphocytes, disrupted CD4?/CD8? ratio and increased
number of CD25? and T cell receptor (TCR) cd cells in
peripheral blood (Eversole 1997; Lewkowicz et al. 2003;
Nowak and Go´rska 2008). Therefore, to determine the
mechanism of the immunologic response in RAS, it was
necessary to define the cytokine profile in patients suffering
from this disease. Many authors suggest that the Th1 type
immunologic response is the one to play the crucial role in
the development of RAS (Albanidou-Farmaki et al. 2007;
Borra et al. 2004; Bun˜o et al. 1998; Lewkowicz et al. 2004,
2011).
Significantly higher secretion of Th1 cytokines in RAS
patients in comparison to the controls was described by
Lewkowicz et al. (2004). The increased production of IL-2,
IFN-c and TNF-a by the peripheral blood mononuclear
cells was observed both in the acute phase of the disease
and in the remission. Meanwhile, the secretion of anti-
inflammatory cytokines TGF-b and IL-10 was significantly
decreased in RAS patients compared to the healthy con-
trols. This observation confirms that the imbalance in pro-
and anti-inflammatory cytokines’ production may contrib-
ute to the development of autoimmunisation and RAS in
predisposed subjects. Similarly, Albanidou-Farmaki et al.
(2007) found the increased number of T lymphocytes able
to produce pro-inflammatory cytokines (IL-2, IL-12 and
IFN-c) and the decreased number of IL-10-producing cells
in peripheral blood of the RAS patients in comparison to
the healthy controls. Also Borra et al. (2004) demonstrated
the increased expression of Th1 type response gene cluster
Fig. 3 Mechanisms of the
disrupted immunologic response
in RAS
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in comparison to Th2 gene cluster in patients with RAS.
The authors emphasized that also some physiologic states
or therapeutics (e. g. pregnancy, nicotine exhibition,
glucocorticoid, thalidomide and tetracycline treatment) are
well known as the Th1 type immunologic response inhib-
itors; therefore, they may influence the course of RAS.
Increased activity of the Th1 type immunologic response
was also observed in some other autoimmune-mediated
conditions like Crohn’s disease, celiac disease and PFAPA
(periodic fever, aphthous stomatitis, pharyngitis and ade-
nitis) syndrome (Yao and Furst 2008). Apart from the
decreased expression of anti-inflammatory cytokines, sig-
nificantly decreased expression of heat shock protein 27
was observed in the oral mucosa of the RAS patients
(Miyamoto et al. 2008). Heat shock proteins manifest the
property to inhibit the expression of pro-inflammatory
cytokines and they participate in the inhibition of the
monocytes differentiation into the dendritic cells. The
decrement in the concentration of that protein fraction may,
therefore, exacerbate the inflammation. The elevated levels
of heat shock protein were observed in tobacco smokers,
which may partially explain the phenomenon of the lower
incidence of aphthae in smokers compared to non-smokers
(Miyamoto et al. 2008). Moreover, in the latter study,
Lewkowicz et al. (2008) demonstrated the decreased effi-
cacy of Treg CD4?CD25? cells in the inhibition of the pro-
inflammatory cytokines’ secretion by CD4? effector T
lymphocytes in the RAS patients compared to the controls
with no systemic diseases.
Bun˜o et al. (1998) attempted to determine the concen-
tration of pro-inflammatory cytokines directly in the oral
mucosa of patients with RAS and they demonstrated sig-
nificantly increased levels of IL-2, IL-4, IL-5, IFN-c and
TNF-a together with a decreased concentration of anti-
inflammatory cytokine IL-10 in the examined group when
compared to healthy controls. These results indicate that
the complex mode of the immune response participates in
the development of RAS. On the one hand, the authors
demonstrated the elevated concentration of pro-inflamma-
tory cytokines in the oral mucosa affected with aphthae
(Th1 type response), but on the other hand the increased
levels of Th2 type cytokines (IL-4, IL-5) were also
detected.
Nowak and Go´rska (2008) compared the concentration
of IL-2 in the peripheral blood and in stimulated saliva in
patients with RAS and in healthy volunteers. They have
demonstrated significantly increased levels of this pro-
inflammatory cytokine in the blood samples of RAS
patients in comparison to controls; however, no significant
differences were detected in stimulated saliva. According
to the authors these results suggests that IL-2 can be pro-
duced by T lymphocytes.
The role of TNF-a, another pro-inflammatory cytokine,
in the development of aphthae was confirmed in the study
by Natah et al. (2000a), who compared the number of TNF-
a-containing cells in the oral mucosa affected by aphthae
and in the mechanically injured oral mucosa bioptates.
Cells rich in TNF-a were observed much more frequently




Mechanism of the immune system disruption in RAS References
IL-2, IFN-c, TNF-a PBMC : production Lewkowicz et al. (2004); Poland
TGF-b, IL-10 ; production
IL-2, IL-12, IFN-c PBMC : production Albanidou-Farmaki et al. (2007); Greece
IL-10 ; production
IL-2, IL-4, IL-5, IFN-c, TNF-a Oral mucosa : concentration Bun˜o et al. (1998); USA
IL-10 ; concentration
IL-2 Blood : concentration Nowak and Go´rska (2008); Poland
Saliva No differences between RAS subjects and healthy
controls
TNF-a Oral mucosa : concentration of TNF-a-containing cells Natah et al. (2000a); Finland
Oral mucosa : concentration of TCR cd lymphocytes Natah et al. (2000b); Finland
Blood : concentration of TCR cd lymphocytes Freysdottir et al. (1999); Great Britain
Oral mucosa : expression of Th1 type response gene cluster
compared to Th2
Borra et al. (2004); Brazil
IL-10 Oral mucosa ; tissue expression Miyamoto et al. (2008); Brazil
HSP27
; Treg CD4?CD25? efficacy in the inhibition of
proinflammatory cytokines secretion by the effector
CD4? T lymphocytes
Lewkowicz et al. (2008); Poland
PBMC peripheral blood mononuclear cells, HSP27 heat shock protein 27
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in biologic material received from the RAS patients, which
suggests the role of the tested cytokine in the lymphocytes
activation and recruitment in the course of the disease. In
the other study, Natah et al. (2000b) also found a signifi-
cant elevation of TCR cd cells number in the oral mucosa
with aphthous lesions. Lymphocytes with T c/d cell
receptors produce IL-2, manifest cytotoxic properties and
destroy some certain virus-infected cells. They also play
role in the process of epithelial growth control. Previous
observations confirmed the elevated concentration of that
type cells in the subjects with rheumatoid arthritis, tuber-
culosis and celiac disease. The results of Natah et al.
(2000b) study revealed that the local elevation in TCR cd
cells number was also found in the oral mucosa in RAS
patients. However, the biological role of those cells in the
process of the aphthous ulcer formation and healing still
remains not clearly understood. Similar conclusions were
presented by Freysdottir et al. (1999), who observed the
increased TCR cd cells’ concentration in the peripheral
blood of patients with Behc¸et’s syndrome and RAS.
In Table 3, we summarized the role of inflammatory
mediators in the etiopathogenesis of RAS based on Polish
and foreign studies.
The common occurrence of aphthae was also described
in patients with HIV, who manifested the disturbed pro-
portion of CD4 and CD8 lymphocytes (Aydemir et al.
2004). The decreased CD4:CD8 ratio has been also found
in RAS patients not affected by HIV; studies results,
however, are not consistent in this matter (Aydemir et al.
2004; Lewkowicz et al. 2008).
Ambiguous conclusions on the immunologic processes
in RAS were also stated in studies performed with the
use of immunofluorescent methods. Wilhelmsen et al.
(2008) did not reveal the deposits of immune complexes
in the oral mucosa specimens received from patients with
RAS. Such deposits are characteristic for certain auto-
immune-mediated vesiculo-bullous diseases, like
Pemphigus vulgaris and Pemphigoid. The lack of
immune complexes in RAS could, therefore, become an
important differentiating marker between RAS and vesi-
culo-bullous diseases. Some other authors, however,
observed the deposits of IgG, IgM and IgA in the epi-
thelial stratum spinosum in RAS and in Behc¸et syndrome
(Williams and Lehner 1977).
Conclusion
The presented studies’ results confirm the crucial role of
the immunologic disturbances in the etiopathogenesis of
RAS. Conclusions from the genetic research support the
thesis that the immune system’s hyper-reactivity in
response to some trigger factors in patients with RAS is at
least partially related with a genetic predisposition—cer-
tain polymorphisms in the cytokine encoding genes
implicate a higher predisposition to RAS. As the etio-
pathogenesis of the condition has not been clearly defined,
the treatment is mainly symptomatic and not very effec-
tive. Discovering the direct etiopathogenetic factors in
RAS may in future help to predict the risk of the disease
occurrence and to develop the effective, causative man-
agement. Inconsistent results of the multiple international
studies focused on genetic and immunologic background
of the condition and insufficient number of that type
research on Polish population indicate a necessity to
perform such an analysis also in our country.
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